Cidp

Chronic inflammatory demyelinating polyradiculoneuropathy, or CIDP, is a neurological condition in which the immune system mistakenly damages the myelin covering of peripheral nerves. Myelin helps nerve signals travel quickly, so this damage can cause weakness, numbness, tingling and balance problems. Symptoms usually develop gradually or recur over at least eight weeks. CIDP can affect adults and, less often, children, with symptoms and severity varying from person to person.

CIDP symptoms often begin in the legs and may gradually involve the arms. Some people develop symptoms steadily, while others have periods of worsening and improvement. The first symptoms of CIDP can be subtle and may affect strength, sensation, balance or endurance.

CIDP occurs when the immune system mistakenly attacks the myelin covering and sometimes other parts of peripheral nerves. This damage slows or blocks nerve signals, which can lead to weakness, sensory changes and reduced reflexes. The immune attack may affect nerve roots as well as nerves farther out in the limbs.

The exact trigger is often unknown. Some cases are associated with another illness or immune condition, but an association does not prove that the illness caused CIDP. CIDP is an autoimmune neurological disorder, not an infection, and it is not contagious.

These are associations, not guaranteed causes or predictors. Many people with CIDP have no identifiable risk factor, and lifestyle choices generally do not cause this disease.

CIDP diagnosis is based on the pattern of progressive or relapsing weakness and sensory changes, findings on a neurological examination, and evidence that signals are slowed in the peripheral nerves. Reduced or absent reflexes can support the diagnosis. No single test confirms every case, so neurologists combine several findings.

Clinicians may also test for alternative causes such as diabetes, vitamin deficiencies, infections, inherited neuropathies or related immune disorders. This process helps distinguish CIDP from other types of peripheral neuropathy.

CIDP treatment aims to calm the immune attack, improve strength and function, prevent relapses and limit permanent nerve damage. Treatment is usually planned and monitored by a neurologist, with adjustments based on symptoms, examination findings and response. The best approach varies among people with CIDP.

Physical and occupational therapy can support strength, movement and daily activities. Fall prevention, mobility aids, pain management, home exercise guidance and regular monitoring for treatment response and adverse effects are also important parts of CIDP medical care.

CIDP may improve substantially with treatment, remain stable, or follow a relapsing course. Some people need long-term therapy or monitoring, while others can reduce treatment after improvement. Recovery can take months because damaged nerves heal slowly, and strength may return gradually.

CIDP itself often does not shorten life expectancy, although severe weakness, breathing problems, falls, associated illnesses and treatment complications can affect health outcomes. Regular follow-up helps clinicians manage relapses, disability and treatment risks. The long-term outlook is often better when treatment begins before substantial nerve damage develops.